Navigation Links
New Anti-TNF Study Shows Patients With Rheumatoid Arthritis Receiving REMICADE® After Inadequate Response to Enbrel® or Humira® Demonstrate Marked Clinical Improvement
Date:11/8/2010

to get an infection or make any infection that you have worse.
  • Lymphoma, or any other cancers in adults and children.  
  • Heart failure—new or worsening symptoms, such as shortness of breath, swelling of your ankles or feet, or sudden weight gain.
  • Reactivation of HBV—feeling unwell, poor appetite, tiredness, fever, skin rash and/or joint pain.
  • Liver injury—jaundice (yellow skin and eyes), dark brown urine, right-sided abdominal pain, fever, or severe tiredness.
  • Blood disorders—fever that doesn't go away, bruising, bleeding or severe paleness.
  • Nervous system disorders—numbness, weakness, tingling, changes in your vision or seizures.
  • Allergic reactions during or after the infusion—hives, difficulty breathing, chest pain, high or low blood pressure, swelling of face and hands, and fever or chills.
  • Lupus-like syndrome—chest discomfort or pain that does not go away, shortness of breath, joint pain, rash on the cheeks or arms that gets worse in the sun. The more common side effects with REMICADE are respiratory infections (that may include sinus infections and sore throat), headache, rash, coughing and stomach pain.
  • Psoriasis—new or worsening psoriasis such as red scaly patches or raised bumps on the skin that are filled with pus.  

  • Please read important information about REMICADE, including full U.S. prescribing information and Medication Guide, at www.remicade.com.

    You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

    About Centocor Ortho Biotech, Inc.

    Centocor Ortho Biotech Inc. redefines the standard of care in immunology, nephrology, and oncology. Built upon a pioneering history, Centocor Orth
    '/>"/>

    SOURCE Centocor Ortho Biotech, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related medicine technology :

    1. New Anti-TNF Golimumab Significantly Reduced Signs and Symptoms of Ankylosing Spondylitis According to Phase 3 Study Findings
    2. Phase 3 Data Show New Anti-TNF, Golimumab, Significantly Improved Arthritis, Skin and Nail Manifestations in Patients with Psoriatic Arthritis
    3. Data From Two Phase 3 Studies Show Anti-TNF Golimumab Significantly Improved Signs and Symptoms of Rheumatoid Arthritis
    4. New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients
    5. SIMPONI(TM) (golimumab) Receives European Approval as Once-Monthly Subcutaneous Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis with Novel SmartJect(TM) Autoinjector
    6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
    7. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
    8. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
    9. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
    10. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
    11. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/15/2014)... NEW YORK , January 15, 2014 ... BreedIT Ltd., the exclusive worldwide distributor of highly sophisticated ... that on January 7, 2014, the Company,s board of ... Ben-Zion Weiner as its new member of the ...
    (Date:1/15/2014)... 2014  Echo Therapeutics, Inc. (Nasdaq: ECTE ) ... System as a non-invasive, wireless continuous glucose monitoring system, ... Chairman and Interim CEO of Echo Therapeutics, will present ... Conference. Mr. Doman will make a ...
    (Date:1/15/2014)... Pharmaceuticals International, Inc. (NYSE: VRX and ... the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ("HSR") with ... indirect wholly-owned subsidiary, Sapphire Subsidiary Corp. ("Purchaser"), for all ... Medical, Inc. (NASDAQ: SLTM ) ("Solta") at ...
    Breaking Medicine Technology:BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3
    ... 2011 Reportlinker.com announces that a new market research ... Pain Therapeutics - Drugs, Markets and Companies ... report describes the latest concepts of pathomechanisms of pain ... pharmacotherapies for pain. Major segments of the pain market ...
    ... Pharmacotherapy research is set to become vastly more ... Wolters Kluwer Pharma Solutions , parent of the ... scientific information and analytics to professionals in the pharmaceutical and ... access (OA) publishing option for authors submitting original research articles ...
    Cached Medicine Technology:Reportlinker Adds Pain Therapeutics - Drugs, Markets and Companies 2Reportlinker Adds Pain Therapeutics - Drugs, Markets and Companies 3Adis Journals Embrace Open Access 2Adis Journals Embrace Open Access 3Adis Journals Embrace Open Access 4
    (Date:4/24/2014)... and irrelevant, could offer an alternative to heart transplants ... Furtado, and her team from the Australian Regenerative Medicine ... fibroblast is a close relative to a cardiomyocyte, the ... research published today in Circulation Research , Dr ... due to their genetic program, and will aid in ...
    (Date:4/24/2014)... national response to the epidemic of prescription opioid overdose ... Journal of Medicine by leaders of agencies in ... The commentary calls upon health care providers to expand ... reduce overdose deaths, and describes a number of misperceptions ... The commentary also discusses how medications can be used ...
    (Date:4/24/2014)... It is better to give than to receive ... a new study suggests. , The study found that 15- ... giving their money to family members, are less likely to ... taking risks or keeping the money for themselves. , The ... National Academy of Sciences . , The study focused on ...
    (Date:4/24/2014)... NH, 4/24/14) Dartmouth has been awarded one of ... serve as a Lead Academic Participating Site in its ... Award recipients are a select groups of investigators charged ... fewer cooperative groups., The NCTN grant system reflects recommendations ... It streamlines operations to achieve four goals:, ...
    (Date:4/24/2014)... The National Science Foundation has awarded LSU ... for Undergraduates (REU) Site grant in the amount ... of undergraduates from diverse social and educational backgrounds, ... Orleans area. The project will provide students ... of 2014-16. It will be led by ...
    Breaking Medicine News(10 mins):Health News:Boring cells could hold the key to heart disease 2Health News:HHS leaders call for expanded use of medications to combat opioid overdose epidemic 2Health News:HHS leaders call for expanded use of medications to combat opioid overdose epidemic 3Health News:HHS leaders call for expanded use of medications to combat opioid overdose epidemic 4Health News:Study: Altruistic adolescents less likely to become depressed 2Health News:Dartmouth awarded lead role in NCI clinical trials network 2Health News:Dartmouth awarded lead role in NCI clinical trials network 3
    ... Yealink ... ... America’s leading supplier of Voice over IP (VoIP) equipment and complete systems, today announced the launch ... phones is comprised of five different SIP based models that range in price from $72 USD ...
    ... At The Parker Center ... surgery. , ... 2010 -- In light of recent media coverage of teens and plastic surgery, including a Today ... a great opportunity to address the right way to approach cosmetic surgery for teens and young ...
    ... ... Shared Hosting Servers , ... Charlotte, NC (PRWEB) May 19, 2010 -- ORCS Web Inc., a specialist in ... solutions announced that Microsoft’s newly released WCF RIA Services for Silverlight 4 has ...
    ... ... Participation from Amicus Capital and Prominent Angel Investors. , ... (PRWEB) May 19, 2010 -- SeniorHomes.com , ... or senior housing, announced today that it received a $1.1 million of Series A ...
    ... Nearly 2.5 million ... Because nearly 90% of eye injuries are preventable with proper protective eyewear, Defog It antifog ... ... Nearly 2.5 million eye injuries occur each year in the United States, with almost half occurring ...
    ... examining expression of every human gene in clear cell renal ... Mayo Clinic,s campus in Florida have discovered gene signatures they ... difficult-to-treat kidney cancer . In the May ... they have discovered: a biological pathway signature of ccRCC for ...
    Cached Medicine News:Health News:VoIP Supply Adds Yealink IP Phones 2Health News:With the Right Approach, Plastic Surgery for Teens and Young Adults is Now a Positive Experience 2Health News:With the Right Approach, Plastic Surgery for Teens and Young Adults is Now a Positive Experience 3Health News:With the Right Approach, Plastic Surgery for Teens and Young Adults is Now a Positive Experience 4Health News:With the Right Approach, Plastic Surgery for Teens and Young Adults is Now a Positive Experience 5Health News:ORCS Web, Inc Makes Available WCF RIA Services 2Health News:SeniorHomes.com Closes $1.1 Million Series A Round of Investment Financing 2Health News:Eye Protection at Home Could Help Prevent 1 Million Home Eye Injures: Tips from Defog It Antifog During National Healthy Vision Month 2010 2Health News:Eye Protection at Home Could Help Prevent 1 Million Home Eye Injures: Tips from Defog It Antifog During National Healthy Vision Month 2010 3Health News:Mayo Clinic researchers find genetic secrets to common kidney cancer 2Health News:Mayo Clinic researchers find genetic secrets to common kidney cancer 3Health News:Mayo Clinic researchers find genetic secrets to common kidney cancer 4
    The new, single-use 26 mL applicator is latex-free, hands-off and sterile to help prevent cross-contamination. The applicator is designed for a smooth delivery of the solution for larger surgical pro...
    ... Anti-HCV Low Titer Performance Panel consists of ... to strong positive for antibodies to the ... for use by manufacturers and diagnostic laboratories ... from all major test systems are included ...
    Comprised of a monofilament polypropylene mesh coated with hydrophilic porcine collagen, Pelvitex™ mesh is clinically proven coating to enhance the healing process, along with the strength and d...
    ... a biological material derived from ... for excellent suppleness and strength. ... ensure high levels of quality ... enhances the biocompatibility, performance and ...
    Medicine Products: